InsidersTradesSigma
Repligen CORP Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Repligen CORP share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Repligen CORP has published 78 insider filings. Market capitalisation: €8.1bn. The latest transaction was reported on 26 June 2026 (Cession). Among the most active insiders: DAWES KAREN A. The full history is accessible without an account.
78
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€5m
18 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Repligen CORP Strong Buy (bullish), based on 20 analysts. Average price target: US$177.05.
43Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 18,548 of 26,270 companies
37.9
score / 100
Value28
Quality48
FCF yld1.1%
Earn yld0.6%
EV/EBITDA48.7x
ROE2.5%
Gross mgn52%
Net mgn6.6%
Debt/EBITDA3.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 26 June 2026
Declarations78 total
733 sharesCommon StockSEC:0001193125-26-285449:0
733 shares@ US$145.00CommonSEC144:0001959173-26-004882
3,832 shares@ US$140.000.0065% mcap100.0% of flowCommon StockSEC:0001193125-26-169682:0
125 shares0Common StockSEC:0001193125-26-093379:0
125 shares0Common StockSEC:0001193125-26-093368:0
1,478 shares@ US$128.7332.0% of flowCommon StockSEC:0001193125-26-087669:0
344 shares@ US$128.732.2% of flowCommon StockSEC:0001193125-26-087595:0
9,897 shares@ US$124.9719.5% of flowCommon StockSEC:0001193125-26-087591:0
327 shares@ US$128.7345.3% of flowCommon StockSEC:0001193125-26-087579:0
444 shares@ US$128.733.2% of flowCommon StockSEC:0001193125-26-087568:0
221 shares@ US$124.97100.0% of flowCommon StockSEC:0001193125-26-087447:0
2,288 shares0Common StockSEC:0001193125-26-010470:0
275 shares@ US$161.003.3% of flowCommon StockSEC:0001193125-25-324912:0
3,366 shares@ US$26.12100.0% of flowCommon StockSEC:0001193125-25-322821:0
2,000 sharesCommon StockSEC:0001193125-25-311290:0
7,041 shares@ US$170.0063.0% of flowCommon StockSEC:0001193125-25-300642:0
2,191 shares@ US$151.2183.4% of flowCommon StockSEC:0001193125-25-288160:0
1,784 shares@ US$151.015.4% of flowCommon StockSEC:0001193125-25-283092:0
25,000 shares@ US$33.8717.8% of flowCommon StockSEC:0001193125-25-280266:0
1,248 shares@ US$145.2325.3% of flowCommon StockSEC:0001193125-25-231365:0
412 shares@ US$121.68100.0% of flowCommon StockSEC:0001193125-25-220202:0
20,000 shares@ US$33.8717.1% of flowCommon StockSEC:0001193125-25-201224:0
1,202 shares0Common StockSEC:0000899243-22-020284:0
644 shares0Common StockSEC:0000899243-22-020280:0
534 shares0Common StockSEC:0000899243-22-020276:0
25 of 78 declarations
About Repligen CORP
Repligen Corp. (NASDAQ: RGEN) is a United States-based life sciences company listed on the NASDAQ market, focused on bioprocessing technologies used in the manufacture of biologic drugs. Headquartered in Waltham, Massachusetts, the company positions itself as a technology partner to pharmaceutical and biotechnology customers producing monoclonal antibodies, recombinant proteins, RNA-based therapeutics, vaccines, and selected cell and gene therapies. While Repligen has a long operating history in life sciences, its current profile is defined by a growth strategy centered on innovation, process efficiency, and the expansion of its proprietary product portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/730272/000095017025038999/rgen-20241231.htm?utm_source=openai)) Operationally, Repligen develops and commercializes a broad set of systems and consumables used across upstream and downstream biomanufacturing workflows. Its portfolio includes filtration solutions, chromatography products, process analytics, and real-time quality and process-control tools. This mix gives the company a specialized, high-value position rather than that of a broad industrial supplier. Repligen’s competitive edge comes from its focus on mission-critical process steps, its innovation cadence, and its ability to serve customers seeking higher throughput, better reproducibility, and lower manufacturing risk. In its end markets, the company competes with established life-science tools and bioprocessing suppliers, but it differentiates through technical depth and a customer-centric approach. ([sec.gov](https://www.sec.gov/Archives/edgar/data/730272/000095017025038999/rgen-20241231.htm?utm_source=openai)) Repligen also has a diversified international footprint. Its corporate headquarters are in Waltham, Massachusetts, and most manufacturing sites are in the United States, complemented by key locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden. This geographic spread strengthens supply-chain resilience and gives the company direct access to major global bioprocessing hubs. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2025/Repligen-Launches-the-CTech-SoloVPE-PLUS-System/default.aspx?utm_source=openai)) Recent highlights reinforce the company’s strategic momentum. In early 2026, Repligen reported strong 2025 results and issued 2026 guidance pointing to further revenue growth and operating-margin expansion. During 2025, the company launched the CTech SoloVPE PLUS system, aimed at biopharmaceutical manufacturers, and acquired 908 Devices’ bioprocessing analytics portfolio, adding real-time monitoring and characterization tools. These developments support a clear investment narrative: Repligen is steadily broadening its technology platform and strengthening its position in the higher-value segment of biomanufacturing infrastructure. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2026/Repligen-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx?utm_source=openai))
